Lorcaserin ( DrugBank: Lorcaserin )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
140	ドラベ症候群	2

140. ドラベ症候群

---

臨床試験数 : 116 /  薬物数 : 65 - (DrugBank : 17) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 64

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04572243 (ClinicalTrials.gov)	September 23, 2020	30/9/2020	A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome	A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects With Dravet Syndrome	Epilepsies, Myoclonic	Drug: Placebo;Drug: Lorcaserin	Eisai Inc.	NULL	Recruiting	2 Years	N/A	All	58	Phase 3	United States;Canada
2	NCT04457687 (ClinicalTrials.gov)	June 7, 2018	30/6/2020	Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies	Extended Access Program and Retrospective Chart Review for Lorcaserin in Dravet Syndrome and Other Refractory Epilepsies	Epilepsies, Myoclonic;Drug Resistant Epilepsy	Drug: Lorcaserin	Eisai Inc.	NULL	Available	2 Years	N/A	All			NULL